loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Abrocitinib

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Abrocitinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Grants From Centro Para El Desarrollo Tecnológico Y La Innovación
    Grants From Centro Para El Desarrollo Tecnológico Y La Innovación

    18 Jun 2024

    // PRESS RELEASE

    https://moehs.com/2grants-from-centro-para-el-desarrollo-tecnologico-y-la-innovacion/

    PRESS RELEASE
    18 Jun 2024
    Share Share
    Glenmark partners with Pfizer to launch abrocitinib in India
    Glenmark partners with Pfizer to launch abrocitinib in India

    31 Jan 2024

    // ECONOMIC TIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-partners-with-pfizer-to-launch-abrocitinib-in-india-to-treat-atopic-dermatitis/articleshow/107296402.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

    ECONOMIC TIMES
    31 Jan 2024
    Share Share
    FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO
    FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO

    10 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230210005281/en/FDA-Approves-Pfizers-Supplemental-New-Drug-Application-for-CIBINQO%C2%AE-abrocitinib

    BUSINESSWIRE
    10 Feb 2023
    Share Share
    2022 drug approvals: Biopharma delivered 37 new drugs
    2022 drug approvals: Biopharma delivered 37 new drugs

    03 Jan 2023

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come

    Kevin Dunleavy FIERCE PHARMA
    03 Jan 2023
    Share Share
    EMA backs restrictions on certain immune-regulating drugs
    EMA backs restrictions on certain immune-regulating drugs

    12 Nov 2022

    // BIOPHARMADIVE

    https://www.biopharmadive.com/news/ema-recommends-jak-inhibitors-restrictions/636343/

    BIOPHARMADIVE
    12 Nov 2022
    Share Share
    JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
    JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC

    01 Nov 2022

    // Catherine Eckford EUROPEANPHARMACEUTICALREVIEW

    https://www.europeanpharmaceuticalreview.com/news/175849/jak-inhibitors-unsafe-for-cardiovascular-cancer-risk-prac/

    Catherine Eckford EUROPEANPHARMACEUTICALREVIEW
    01 Nov 2022
    Share Share